Challenges and future prospects of antibiotic therapy: From peptides to phages utilization

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Mandal, Santi M ^a   Roy, Anupam ^a   Ghosh, Ananta K ^a   Hazra, Tapas K ^b   Basak, Amit ^a   Franco, Octavio L ^c  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

Author keywords

Antibiotics; Infection control; Multi drug resistant pathogens

Indexed keywords

4 [N (1,8 NAPHTHALIMIDE)] N BUTYRIC ACID; ALKALOID; ANTIBIOTIC AGENT; ARCHAEOCIN; BACTERIOPHAGE DNA; BERBERINE; BIOCHANIN A; CAFFEOYLQUINIC ACID; EFFLUX PUMP INHIBITOR; EPIGALLOCATECHIN GALLATE; ESSENTIAL OIL; FLAVONE; FLAVONOID; GENISTEIN; LIPOPOLYSACCHARIDE; METALLOANTIBIOTIC AGENT; MYXOPYRONIN; PD 404182; PEPTIDOMIMETIC AGENT; PHENOL; PLEUROCIDIN; POLYPEPTIDE ANTIBIOTIC AGENT; RESERPINE; RIFAMPICIN; SAPONIN; SPINOSAN A; SYLIBIN; TERPENOID; THYMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIOPHAGE; CHOLERA; DRUG MISUSE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; FOOD SAFETY; GENETIC ENGINEERING; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84904688494     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00105     Document Type: Review

References (128)

1. Andreu, D., and Rivas, L. (1998). Animal antimicrobial peptides: an overview. Biopolymers 47, 415-433. doi: 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D
2. Andrushchenko, V. V., Aarabi, M. H., Nguyen, L. T., Prenner, E. J., and Vogel, H. J. (2008). Thermodynamics of the interactions of tryptophan-rich cathelicidin antimicrobial peptides with model and natural membranes. Biochim. Biophys. Acta 1778, 1004-1014. doi: 10.1016/j.bbamem.2007.12.022
3. Andrushchenko, V. V., Vogel, H. J., and Prenner, E. J. (2007). Interactions of tryptophan- rich cathelicidin antimicrobial peptides with model membranes studied by differential scanning calorimetry. Biochim. Biophys. Acta 1768, 2447-2458. doi: 10.1016/j.bbamem.2007.05.015
4. Antibiotic resistance threats in the United States. (2013). Centers for Disease Control and Prevention. Atlanta, GA: US Department of Health and Human Services.
5. Arnusch, C. J., Pieters, R. J., and Breukink, E. (2012). Enhanced membrane pore formation through high- affinity targeted antimicrobial peptides. PLoS ONE 7:e39768. doi: 10.1371/journal.pone.0039768
6. Belogurov, G. A., Vassylyeva, M. N., Sevostyanova, A., Appleman, J. R., Xiang, A. X., Lira, R., et al. (2009). Transcription inactivation through local refolding of the RNA polymerase structure. Nature 457, 332-335. doi: 10.1038/nature07510
7. Bhardwaj, A. K., and Mohanty, P. (2012). Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. Recent Pat. Antiinfect. Drug Disc. 7, 73-89. doi: 10.2174/157489112799829710
8. Birck, M. R., Holler, T. P., and Woodard, R. W. (2000). Identification of a slow tight-binding inhibitor of 3-deoxy-d-manno-octulosonic acid 8-phosphate synthase. J. Am. Chem. Soc. 122, 9334-9335. doi: 10.1021/ja002142z
9. Boman, H. G., Agerberth, B., and Boman, A. (1993). Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61, 2978-2984.
10. Borysowski, J., Miêdzybrodzki, R., and Caister, A. G. (2011). Phage Therapy: Current Research and Applications, eds J. Borysowski, R. Midezybrodzki, and A. Górski (Poole: Caister Academic Press).
11. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12. doi: 10.1086/595011
12. Bremner, J. B. (2007). Some approaches to new antibacterial agents. Pure Appl. Chem. 79, 2143-2153. doi: 10.1351/pac200779122143
13. Brincat, J. P., Carosati, E., Sabatini, S., Manfroni, G., Fravolini, A., Raygada, J. L., et al. (2011). Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. J. Med. Chem. 54, 354-365. doi: 10.1021/jm1011963
14. Brogden, K. A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250. doi: 10.1038/nrmicro1098
15. Brotz, H., Bierbaum, G., Leopold, K., Reynolds, P. E., and Sahl, H. G. (1998). The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42, 154-160. doi: 10.1186/1471-2180-8-186
16. Brüssow, H., Canchaya, C., and Hardt, W. D. (2004). Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol. Mol. Biol. Rev. 68, 560-602. doi: 10.1128/MMBR.68.3.560-602.2004
17. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., et al. (2001). Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912. doi: 10.1016/S0092-8674(01)00286-0
18. Chan, D. I., Prenner, E. J., and Vogel, H. J. (2006). Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 1758, 1184-1202. doi: 10.1016/j.bbamem.2006.04.006
19. Cheung, S. T., Chang, D., Ming-Lum, A., and Mui, A. L. F. (2013). Interleukin-10 inhibits lipopolysaccharide induced miR- 155 precursor stability and maturation. PLoS ONE 8:e71336. doi: 10.1371/journal.pone.0071336
20. Chohan, Z. H., Supuran, C. T., and Scozzafava, A. (2005). Metal binding and antibacterial activity of ciprofloxacin complexes. J. Enzyme Inhib. Med. Chem. 20, 303-307. doi: 10.1080/14756360310001624948
21. Chuang, C. H., Su, L. H., Perera, J., Carlos, C., Tan, B. H., Kumarasinghe, G., et al. (2008). Surveillance of antimicrobial resistance of Salmonella enterica serotype Typhi in seven Asian countries. Epidemiol. Infect. 12, 1-4. doi: 10.1017/S0950268808000745
22. Cole, A. M., Liao, H. I., Ganz, T., and Yang, O. O. (2003). Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett. 535, 195-199. doi: 10.1016/S0014-5793(02)03860-7
23. Cowan, M. M. (1999). Plant products as antimicrobial agents. Clin. Microbiol. Rev. 12, 564-582.
24. d'Herelle, F. (1917). Sur un microbe invisible antagoniste des bacteries dysenteriques. C. R. Acad. Sci. 165, 373-375.
25. Daniells, S. (2006). FDA Approves Viruses as Food Additive for Meats. Available at: http://www.foodnavigator-usa.com/Suppliers2/FDA-approves-viruses-as-food-additive-for-meats
26. Davies, J. (1994). Inactivation of antibiotics and the dissemination of resistance genes. Science 15, 375-382. doi: 10.1126/science.8153624
27. Delmar, J. A., Su, C. C., and Yu, E. W. (2014). Bacterial multidrug efflux transporters. Annu. Rev. Biophys. doi: 10.1146/annurev-biophys-051013-022855 [Epub ahead of print].
28. Desgranges, S., Ruddle, C. C., Burke, L. P., McFadden, T. M., O'Brien, J. E., Fitzgerald-Hughes, D., et al. (2012). ß-Lactam-host defense peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. RSC Adv. 2, 2480-2492. doi: 10.1039/c2ra01351g
29. Deslouches, B., Islam, K., Craigo, J. K., Paranjape, S. M., Montelaro, R. C., and Mietzner, T. A. (2005a). Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother. 49, 3208-3216. doi: 10.1128/AAC.49.8.3208-3216.2005
30. Deslouches, B., Phadke, S. M., Lazarevic, V., Cascio, M., Islam, K., Montelaro, R. C., et al. (2005b). De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob. Agents Chemother. 49, 316-322. doi: 10.1128/AAC.49.1.316-322.2005
31. Deslouches, B., Steckbeck, J. D., Craigo, J. K., Doi, Y., Mietzner, T. A., and Montelaro, R. C. (2013). Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob. Agents. Chemother. 57, 2511-2521. doi: 10.1128/AAC.02218-12
32. Devocelle, M. (2012). Targeted antimicrobial peptides. Front. Immunol. 3:309. doi: 10.3389/fimmu.2012.00309
33. Eda, S., Mitsui, H., and Minamisawa, H. (2011). Involvement of the SmeAB multidrug efflux pump in resistance to plant antimicrobials and contribution to nodulation competitiveness in Sinorhizobium meliloti. Appl. Environ. Microbiol. 77, 2855-2862. doi: 10.1128/AEM.02858-10
34. Fjell, C. D., Hiss, J. A., Hancock, R. E. W., and Schneider, G. (2012). Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11, 37-51. doi: 10.1038/nrd3591
35. Ganz, T. (2003). Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720. doi: 10.1038/nri1180
36. Giuliani, A., Pirri, G., and Nicoletto, S. F. (2007). Antimicrobial peptides: an overview of a promising class of therapeutics. CEJB 2, 1-33. doi: 10.2478/s11535-007-0010-5
37. Gordon, Y. J., Romanowski, E. G., and McDermott, A. M. (2005). A review of antimicrobial peptides and their therapeutic potential as anti infective drugs. Curr. Eye Res. 30, 505-515. doi: 10.1080/02713680590968637
38. Hancock, R. E., and Lehrer, R. (1998). Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16, 82-88. doi: 10.1016/S0167-7799(97)01156-6
39. Hancock, R. E. W. (2001). Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1, 156-164. doi: 10.1016/S1473-3099(01)00092-5
40. Hancock, R. E. W., and Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557. doi: 10.1038/nbt1267
41. Haney, E. F., Nazmi, K., Bolscher, J. G., and Vogel, H. J. (2012a). Influence of specific amino acid side chains on the antimicrobial activity and structure of bovine lactoferrampin. Biochem. Cell Biol. 90, 362-377. doi: 10.1139/o11-057
42. Haney, E. F., Nguyen, L. T., Schibli, D. J., and Vogel, H. J. (2012b). Design of a novel tryptophan-rich membrane-active antimicrobial peptide from the membrane-proximal region of the HIV glycoprotein, gp41. Beilstein J. Org. Chem. 8, 1172-1184. doi: 10.3762/bjoc.8.130
43. Hausler, T. (2006). Viruses vs. Superbugs. A Solution to the Antibiotic Crisis? New York: Macmillan.
44. Heidenau, F., Mittelmeier, W., Detsch, R., Haenle, M., Stenzel, F., Ziegler, G., et al. (2005). A novel antibacterial titania coating: metal ion toxicity and in vitro surface colonization. J. Mater. Sci. Mater. Med. 16, 883-888. doi: 10.1007/s10856-005-4422-3
45. Herrmann, M., and Laxminarayan, R. (2010). Antibiotic effectiveness: new challenges in natural resource management. Annu. Rev. Resour. Econ. 2, 125-138. doi: 10.1146/annurev.resource.050708.144125
46. Ho, M. X., Hudson, B. P., Das, K., Arnold, E., and Ebright, R. H. (2009). Structures of RNA polymerase-antibiotic complexes. Curr. Opin. Struct. Biol. 19, 715-723. doi: 10.1016/j.sbi.2009.10.010
47. Holler, J. G., Christensen, S. B., Slotved, H. C., Rasmussen, H. B., Guzman, A., Olsen, C. E., et al. (2012a). Novel inhibitory activity of the Staphylococcus aureus NorA efflux pump by a kaempferol rhamnoside isolated from Persea lingue Nees. J. Antimicrob. Chemother. 67, 1138-1144. doi: 10.1093/jac/dks005
48. Holler, J. G., Slotved, H. C., Molgaard, P., Olsen, C. E., and Christensen, S. B. (2012b). Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles. Bioorg. Med. Chem. 20, 4514-4521. doi: 10.1016/j.bmc.2012.05.025
49. Housby, J. N., and Mann, N. H. (2009). Phage therapy. Drug Discov. Today 14, 536-540. doi: 10.1016/j.drudis.2009.03.006
50. Hsieh, P. C., Siegel, S. A., Rogers, B., Davis, D., and Lewis, K. (1998). Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc. Natl. Acad. Sci. U.S.A. 95, 6602-6606. doi: 10.1073/pnas.95.12.6602
51. Hudson, A., Imamura, T., Gutteridge, W., Kanyok, T., and Nunn, P. (2003). The Current Anti-TB Drug Research and Development Pipeline. Available at: http://www.who.int/tdr/publications/documents/anti-tb-drug.pdf
52. Huff, W. E., Huff, G. R., Rath, N. C., Balog, J. M., and Donoghue, A. M. (2004). Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult. Sci. 83, 1944-1947. doi: 10.1093/ps/83.12.1944
53. Hung, D. T., Shakhnovich, E. A., Pierson, E., and Mekalanos, J. J. (2005). Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670-674. doi: 10.1126/science.1116739
54. Inal, J. M. (2003). Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch. Immunol. Ther. Exp. (Warsz.) 51, 237-244.
55. Irschik, H., Gerth, K., Höfle, G., Kohl, W., and Reichenbach, H. (1983). The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales). J. Antibiot. (Tokyo) 36, 1651-1658. doi: 10.7164/antibiotics.36.1651
56. Jagannathan, R., Poddar, P., and Prabhune, A. (2007). Cephalexin-mediated synthesis of quasi-spherical and anisotropic gold nanoparticles and their in situ capping by the antibiotic. J. Phys. Chem. C 111, 6933-6938. doi: 10.1021/jp067645r
57. Jayaraman, P., Sakharkar, K. R., Lim, C., Siddiqi, M. I., Dhillon, S. K., and Sakharkar, M. K. (2013). Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR. Drug Des. Devel. Ther. 7, 449-475. doi: 10.2147/DDDT.S43964
58. Jayaraman, P., Sakharkar, M. K., Lim, C. S., Tang, T. H., and Sakharkar, K. R. (2010). Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int. J. Biol. Sci. 6, 556-568. doi: 10.7150/ijbs.6.556
59. Jenssen, H., Hamill, P., and Hancock, R. E. W. (2006). Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511. doi: 10.1128/CMR.00056-05
60. Jing, W., Hunter, H. N., Hagel, J., and Vogel, H. J. (2003). The structure of the antimicrobial peptide Ac-RRWWRF-NH2 bound to micelles and its interactions with phospholipid bilayers. J. Peptide Res. 61, 219-229. doi: 10.1034/j.1399-3011.2003.00050.x
61. Kalia, N. P., Mahajan, P., Mehra, R., Nargotra, A., Sharma, J. P., Koul, S., et al. (2012). Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. J. Antimicrob. Chemother. 67, 2401-2408. doi: 10.1093/jac/dks232
62. Karl, T. (2004). Old dogma, new tricks-21st Century phage therapy. Nat. Biotechnol. 22, 31-36. doi: 10.1038/nbt0104-31
63. Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Wettig, S., and Slavcev, R. (2012). Immunocompatibility of bacteriophages as nanomedicines. J. Nanotech. 2012, 1-13. doi: 10.1155/2012/247427
64. Kozuma, S., Takahata, Y. H., Fukuda, D., Kuraya, N., Nakajima, M., and Ando, O. (2013). Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria. J. Antibiot. 67, 237-242.
65. Laverty, G., McLaughlin, M., Shaw, C., Gorman, S. P., and Gilmore, B. F. (2010). Antimicrobial activity of short, synthetic cationic lipopeptides. Chem. Biol. Drug Des. 75, 563-569. doi: 10.1111/j.1747-0285.2010.00973.x
66. Levy, S. B. (2002). The Antibiotic Paradox: How the Misuse of Antibiotics Destroys their Curative Powers, 2nd Edn. Cambridge, MA: Perseus Publishing.
67. Levy, S. B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, S122-S129. doi: 10.1038/nm1145
68. Lewis, K. (2001). In search of natural substrates and inhibitors of MDR pumps. J. Mol. Microbiol. Biotechnol. 3, 247-254.
69. Lewis, K., and Ausubel, F. M. (2006). Prospects for plant-derived antibacterials. Nat. Biotechnol. 24, 1504-1507. doi: 10.1038/nbt1206-1504
70. Lindemann, R. A. (1988). Bacterial activation of human natural killer cells: role of cell surface lipopolysaccharide. Infect. Immun. 56, 1301-1308.
71. López, R., García, E., García, P., and García, J. L. (1997). The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb. Drug Resist. 3, 199-211. doi: 10.1089/mdr.1997.3.199
72. Lu, T. K., and Collins, J. J. (2009). Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 4629-4634. doi: 10.1073/pnas.0800442106
73. Lu, T. K., and Koeris, M. S. (2011). The next generation of bacteriophage therapy. Curr. Opin. Microbiol. 14, 524-531. doi: 10.1016/j.mib.2011.07.028
74. Mandal, S. M., Sharma, S., Pinnaka, A. K., Kumari, A., and Korpole, S. (2013). Isolation and characterization of diverse antimicrobial lipopeptides produced by Citrobacter and Enterobacter. BMC Microbiol. 13:152. doi: 10.1186/1471-2180-13-152
75. Marquez, B. (2005). Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87, 1137-1147. doi: 10.1016/j.biochi.2005.04.012
76. Marshall, S. H., and Arenas, G. (2003). Antimicrobial peptides: a natural alternative to chemical antibiotics and a potential for applied biotechnology. Electron. J. Biotechnol. 6:2. doi: 10.2225/vol6-issue3-fulltext-1
77. Martin, E., Ganz, T., and Lehrer, R. I. (1995). Defensins and other endogenous peptide antibiotics of vertebrates. J. Leukoc. Biol. 58, 128-136.
78. Matsuzaki, K., Murase, O., Fujii, N., and Miyajima, K. (1996). An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 35, 11361-11368. doi: 10.1021/bi960016v
79. Maurois, A. (1959). Life of Sir Alexander Fleming: Discoverer of Penicillin. London: E. P. Dutton & Co., Inc.
80. Maurya, I. K., Thota, C. K., Verma, S. D., Sharma, J., Rawal, M. K., Ravikumar, B., et al. (2013). Rationally designed transmembrane peptide mimics of the multidrug transporter protein Cdr1 act as antagonists to selectively block drug efflux and chemosensitize azole-resistant clinical isolates of Candida albicans. J. Biol. Chem. 288, 16775-16787. doi: 10.1074/jbc.M113.467159
81. McGrath, S., Fitzgerald, G. F., and van Sinderen, D. (2004). The impact of bacteriophage genomics. Curr. Opin. Biotechnol. 15, 94-99. doi: 10.1016/j.copbio.2004.01.007
82. Mesyanzhinov, V. V., Robben, J., Grymonprez, B., Kostyuchenko, V. A., Bourkaltseva, M. V., Sykilinda, N. N., et al. (2002). The genome of bacteriophage fKZ of Pseudomonas aeruginosa. J. Mol. Biol. 317, 1-19. doi: 10.1006/jmbi.2001.5396
83. Michael, P. D., Loneragan, G. H., Scott, M., and Singer, R. S. (2013). Antimicrobial resistance: challenges and perspectives. Compr. Rev. Food Sci. Food Saf. 12, 234-248. doi: 10.1111/1541-4337.12008
84. Miki, T., and Hardt, W.-D. (2013). Outer membrane permeabilization is an essential step in the killing of gram-negative bacteria by the lectin RegIIIß. PLoS ONE 8:e69901. doi: 10.1371/journal.pone.0069901
85. Ming, L. J. (2003). Structure and function of "metalloantibiotics." Med. Res. Rev. 23, 697-762. doi: 10.1002/med.10052
86. Mukhopadhyay, J., Das, K., Ismail, S., Koppstein, D., Jang, M., Hudson, B., et al. (2008). The RNA polymerase "switch region" is a target for inhibitors. Cell 135, 295-307. doi: 10.1016/j.cell.2008.09.033
87. Nakaido, H. (1994). Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 15, 382-388. doi: 10.1126/science.8153625
88. Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., et al. (2012). Endolysins as antimicrobials. Adv. Virus Res. 83, 299-365. doi: 10.1016/B978-0-12-394438-2.00007-4
89. Nguyen, L. T., Chau, J. K., Perry, N. A., de Boer, L., Zaat, S. A., and Vogel, H. J. (2010). Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS ONE 5:12684. doi: 10.1371/journal.pone.0012684
90. O'Connor, E. M., and Shand, R. F. (2002). Halocins and sulfolobicins: the emerging story of archaeal protein and peptide antibiotics. J. Ind. Microbiol. Biotechnol. 28, 23-31. doi: 10.1038/sj/jim/7000190
91. Oren, Z., and Shai, Y. (1998). Mode of action of linear amphipathic a-helical antimicrobial peptides. Biopolymers 47, 451-463. doi: 10.1002/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F
92. Palmer, J. D., and Rifkind, D. (1974). Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg. Gynecol. Obstet. 138, 755-759.
93. Parfitt, T. (2005). Georgia: an unlikely stronghold for bacteriophage therapy. Lancet 365, 2166-2167. doi: 10.1016/S0140-6736(05)66759-1
94. Park, C. B., Kim, H. S., and Kim, S. C. (1998). Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244, 253-257. doi: 10.1006/bbrc.1998.8159
95. Phadke, S. M., Islam, K., Deslouches, B., Kapoor, S. A., Beer Stolz, D., Watkins, S. C., et al. (2003). Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides 24, 1099-1107. doi: 10.1016/j.peptides.2003.07.001
96. Piddock, L. J. (2006). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19, 382-402. doi: 10.1128/CMR.19.2.382-402.2006
97. Pini, A., Giuliani, A., Falciani, C., Runci, Y., Ricci, C., Lelli, B., et al. (2005). Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49, 2665-2672. doi: 10.1128/AAC.49.7.2665-2672.2005
98. Pokrovskaya, V., and Baasov, T. (2010). Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin. Drug Discov. 5, 883-902. doi: 10.1517/17460441.2010.508069
99. Rai, A., Prabhune, A., and Perry, C. C. (2010). Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. J. Mater. Chem. 20, 6789-6798. doi: 10.1039/c0jm00817f
100. Roy, A., Franco, O. L., and Mandal, S. M. (2013). Biomedical exploitation of self-assembled peptide based nanostructures. Curr. Protein Pept. Sci. 14, 580-587. doi: 10.2174/1389203711209070687
101. Rozek, A., Friedrich, C. L., and Hancock, R. E. W. (2000). Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry 39, 15765-15774. doi: 10.1021/bi000714m
102. Sabatini, S., Gosetto, F., Manfroni, G., Tabarrini, O., Kaatz, G. W., Patel, D., et al. (2011). Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J. Med. Chem. 54, 5722-5736. doi: 10.1021/jm200370y
103. Sakharkar, M. K., Jayaraman, P., Soe, W. M., Chow, V. T., Sing, L. C., and Sakharkar, K. R. (2009). In vitro combinations of antibiotics and phytochemicals against Pseudomonas aeruginosa. J. Microbiol. Immunol. Infect. 42, 364-370.
104. Salomon, R. A., and Farias, R. N. (1992). Microcin 25, a novel antimicrobial peptide produced by Escherichia coli. J. Bacteriol. 174, 7428-7435.
105. Schuch, R., Nelson, D., and Fischetti, V. A. (2002). A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418, 884-889. doi: 10.1038/nature01026
106. Sekhon, B. S. (2010). Metalloantibiotics and antibiotic mimics - an overview. J. Pharm. Educ. Res. 1, 1-20.
107. Shi, J., Ross, C. R., Chengappa, M. M., Sylte, M. J., McVey, D. S., and Blecha, F. (1996). Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide. Antimicrob. Agents Chemother. 40, 115-121.
108. Silvestro, L., Gupta, K., Weiser, J. N., and Axelsen, P. H. (1997). The concentration-dependent membrane activity of cecropin A. Biochemistry 36, 11452-11460. doi: 10.1021/bi9630826
109. Skurnika, M., and Strauch, E. (2006). Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5-14. doi: 10.1016/j.ijmm.2005.09.002
110. Smith, A. (2004). "Bacterial resistance to antibiotics," in Hugo and Russell's Pharmaceutical Microbiology, 7th Edn, eds S. P. Denyer, N. A. Hodges, and S. P. Gorman (Malden, MA: Blackwell Science).
111. Spellberg, B., Bartlett, J. G., and Gilbert, D. N. (2013). The future of antibiotics and resistance. N. Engl. J. Med. 368, 299-302. doi: 10.1056/NEJMp1215093
112. Spratt, B.G. (1994). Resistance to antibiotics mediated by target alterations. Science 15, 388-393. doi: 10.1126/science.8153626
113. Srivastava, A., Talaue, M., Liu, S., Degen, D., Ebright, R. Y., Sineva, E., et al. (2011). New target for inhibition of bacterial RNA polymerase: "switch region." Curr. Opin. Microbiol. 14, 532-543. doi: 10.1016/j.mib.2011.07.030
114. Stella, V. J. (2004). Prodrugs as therapeutics. Expert Opin. Ther. Patents 14, 277-280. doi: 10.1517/13543776.14.3.277
115. Stermitz, F. R., Lorenz, P., Tawara, J. N., Zenewicz, L. A., and Lewis, K. (2000). Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U.S.A. 97, 1433-1437. doi: 10.1073/pnas.030540597
116. Subbalakshmi, C., and Sitaram, N. (1998). Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 160, 91-96. doi: 10.1111/j.1574-6968.1998.tb12896.x
117. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage Therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
118. Takiff, H. E., Cimino, M., Musso, M. C., Weisbrod, T., Martinez, R., Delgado, M. B., et al. (1996). Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. U.S.A. 93, 362-366. doi: 10.1073/pnas.93.1.362
119. Tamamura, H., Murakami, T., Masuda, M., Otaka, A., Takada, W., Ibuka, T., et al. (1994). Structure- activity relationships of an anti-HIV peptide, T22. Biochem. Biophys. Res. Commun. 205, 1729-1735. doi: 10.1006/bbrc.1994.2868
120. Tencza, S. B., Creighton, D. J., Yuan, T., Vogel, H. J., Montelaro, R. C., and Mietzner, T. A. (1999). Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization. J. Antimicrob. Chemother. 44, 33-41. doi: 10.1093/jac/44.1.33
121. Thota, N., Koul, S., Reddy, M. V., Sangwan, P. L., Khan, I. A., Kumar, A., et al. (2008). Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem. 16, 6535-6543. doi: 10.1016/j.bmc.2008.05.030
122. Urbán, P., Valle-Delgado, J. J., Moles, E., Marques, J., Díez, C., and Fernàndez-Busquets, X. (2012). Nanotools for the delivery of antimicrobial peptides. Curr. Drug Targets 13, 1158-1172. doi: 10.2174/138945012802002302
123. Wang, Z., and Wang, G. (2004). APD: the antimicrobial peptide database. Nucleic Acids Res. 32, 590-592. doi: 10.1093/nar/gkh025
124. Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G., et al. (2003). Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47, 1301-1307. doi: 10.1128/AAC.47.4.1301-1307.2003
125. Wiesler, S. C., Burrows, P. C., and Buck, M. (2012). A dual switch controls bacterial enhancer-dependent transcription. Nucleic Acids Res. 40, 10878-10892. doi: 10.1093/nar/gks844
126. Yang, L., Harroun, T. A., Weiss, T. M., Ding, L., and Huang, H. W. (2001). Barrel-stave model or toroidal model? A case study on melittin pores. Biophys. J. 81, 1475-1485. doi: 10.1016/S0006-3495(01)75802-X
127. Yeung, C. Y., Chiang Chiau, J. S., Chan, W. T., Jiang, C. B., Cheng, M. L., Liu, H. L., et al. (2013). In vitro prevention of Salmonella lipopolysaccharide-induced damages in epithelial barrier function by various Lactobacillus strains. Gastroenterol. Res. Pract. 2013, 6. doi: 10.1155/2013/973209
128. Yonezawa, A., Kuwahara, J., Fujii, N., and Sugiura, Y. (1992). Binding of tachyplesin I to DNA revealed by footprinting analysis: significant contribution of secondary structure to DNA binding and implication for biological action. Biochemistry 31, 2998-3004. doi: 10.1021/bi00126a022